229 related articles for article (PubMed ID: 23259386)
41. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy.
Schmidt N; Neumann-Haefelin C; Thimme R
Dig Dis; 2012; 30(5):483-91. PubMed ID: 23108304
[TBL] [Abstract][Full Text] [Related]
42. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
Shirakawa H; Suzuki H; Shimomura M; Kojima M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Cancer Sci; 2009 Aug; 100(8):1403-7. PubMed ID: 19496787
[TBL] [Abstract][Full Text] [Related]
43. Challenges in cancer vaccine development for hepatocellular carcinoma.
Buonaguro L; Petrizzo A; Tagliamonte M; Tornesello ML; Buonaguro FM
J Hepatol; 2013 Oct; 59(4):897-903. PubMed ID: 23714157
[TBL] [Abstract][Full Text] [Related]
44. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
Ishiguro T; Sugimoto M; Kinoshita Y; Miyazaki Y; Nakano K; Tsunoda H; Sugo I; Ohizumi I; Aburatani H; Hamakubo T; Kodama T; Tsuchiya M; Yamada-Okabe H
Cancer Res; 2008 Dec; 68(23):9832-8. PubMed ID: 19047163
[TBL] [Abstract][Full Text] [Related]
45. Glypican-3 antibodies: a new therapeutic target for liver cancer.
Feng M; Ho M
FEBS Lett; 2014 Jan; 588(2):377-82. PubMed ID: 24140348
[TBL] [Abstract][Full Text] [Related]
46. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.
Shi D; Shi Y; Kaseb AO; Qi X; Zhang Y; Chi J; Lu Q; Gao H; Jiang H; Wang H; Yuan D; Ma H; Wang H; Li Z; Zhai B
Clin Cancer Res; 2020 Aug; 26(15):3979-3989. PubMed ID: 32371538
[TBL] [Abstract][Full Text] [Related]
47. Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy.
Yoshikawa T; Takahara M; Tomiyama M; Nieda M; Maekawa R; Nakatsura T
Int J Oncol; 2014 Nov; 45(5):1847-56. PubMed ID: 25189159
[TBL] [Abstract][Full Text] [Related]
48. Potential of immunotherapy for hepatocellular carcinoma.
Breous E; Thimme R
J Hepatol; 2011 Apr; 54(4):830-4. PubMed ID: 21145836
[TBL] [Abstract][Full Text] [Related]
49. Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma.
Iwahashi M; Katsuda M; Nakamori M; Nakamura M; Naka T; Ojima T; Iida T; Yamaue H
Cancer Sci; 2010 Dec; 101(12):2510-7. PubMed ID: 20874827
[TBL] [Abstract][Full Text] [Related]
50. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein.
Pan Z; Di S; Shi B; Jiang H; Shi Z; Liu Y; Wang Y; Luo H; Yu M; Wu X; Li Z
Cancer Immunol Immunother; 2018 Oct; 67(10):1621-1634. PubMed ID: 30078052
[TBL] [Abstract][Full Text] [Related]
51. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
52. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
[TBL] [Abstract][Full Text] [Related]
53. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
Batra SA; Rathi P; Guo L; Courtney AN; Fleurence J; Balzeau J; Shaik RS; Nguyen TP; Wu MF; Bulsara S; Mamonkin M; Metelitsa LS; Heczey A
Cancer Immunol Res; 2020 Mar; 8(3):309-320. PubMed ID: 31953246
[TBL] [Abstract][Full Text] [Related]
54. Glypican 3 expression in pediatric malignant solid tumors.
Kinoshita Y; Tanaka S; Souzaki R; Miyoshi K; Kohashi K; Oda Y; Nakatsura T; Taguchi T
Eur J Pediatr Surg; 2015 Feb; 25(1):138-44. PubMed ID: 25344940
[TBL] [Abstract][Full Text] [Related]
55. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
Man XB; Tang L; Zhang BH; Li SJ; Qiu XH; Wu MC; Wang HY
Liver Int; 2005 Oct; 25(5):962-6. PubMed ID: 16162153
[TBL] [Abstract][Full Text] [Related]
56. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer.
Kono K; Mizukami Y; Daigo Y; Takano A; Masuda K; Yoshida K; Tsunoda T; Kawaguchi Y; Nakamura Y; Fujii H
Cancer Sci; 2009 Aug; 100(8):1502-9. PubMed ID: 19459850
[TBL] [Abstract][Full Text] [Related]
57. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
[TBL] [Abstract][Full Text] [Related]
58. Identification of nanobodies against hepatocellular carcinoma marker glypican-3.
Wang W; Xu C; Wang H; Jiang C
Mol Immunol; 2021 Mar; 131():13-22. PubMed ID: 33453658
[TBL] [Abstract][Full Text] [Related]
59. Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma.
Tsuchiya N; Yoshikawa T; Fujinami N; Saito K; Mizuno S; Sawada Y; Endo I; Nakatsura T
Oncoimmunology; 2017; 6(10):e1346764. PubMed ID: 29123959
[TBL] [Abstract][Full Text] [Related]
60. Tumor vaccine: current trends in antigen specific immunotherapy.
Baral R
Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
